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Abstract Mammalian mitochondria are known to proliferate in
response to several stimuli. Proliferation requires an increase in
expression of genes encoding proteins involved in mitochondrial
biogenesis, as well as in the replication and expression of
mitochondrial DNA (mtDNA). In contrast, we report that
inhibiting mitochondrial protein synthesis causes a modulation in
mtDNA gene expression without the concomitant increase in
proliferative markers. Further, inhibition results in the produc-
tion of a previously unidentified light-strand mitochondrial RNA
that spans the entire displacement loop, the function of which is
currently unknown. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Mitochondria are known to proliferate in response to sev-
eral external stimuli and in certain mitochondrial disorders [1^
4]. It is, therefore, highly likely that a mechanism exists for co-
ordinating the expression of numerous nuclear genes with ex-
pression of the mitochondrial genome. As all the proteins
involved in mitochondrial gene expression are encoded by
the nucleus, one way to co-ordinate such a mechanism is for
genes encoding mitochondrial proteins crucial for metabolic
function and for regulating mitochondrial DNA (mtDNA)
gene expression to share a common binding site for a tran-
scription factor. Several candidates have been proposed, one
of which is nuclear respiratory factor-1 (NRF-1, [5]). In re-
sponse to electrical stimulation of isolated cardiomyocytes,
conditions that are known to increase the mitochondrial con-
tent of the cell, NRF-1 has been shown to modulate expres-
sion of several nuclear genes encoding mitochondrial proteins
[6]. Stimulation of NRF-1 has also been shown to increase
expression of mtTFA, a mitochondrially destined protein re-
quired for mtDNA replication, consistent with NRF-1 playing
a pivotal role in co-ordinating expression [7,8].
Although an increase in NRF-1 and mtTFA has clearly
been linked with mitochondrial proliferation, there is some
evidence that regulation of mtDNA expression can occur
without proliferation and may be a mechanism for ¢ne-tuning
the amounts of respiratory chain components in response to
chronic energy demands [9]. Most notably, a £uctuation in the
levels of RNA products processed from the three major poly-
cistronic RNA units has been reported in isolated mitochon-
dria on addition of thyroid hormone or in response to varying
concentrations of ATP [10,11]. Whilst the evidence for auton-
omous regulation of mtDNA transcription is compelling, the
exact molecular mechanisms that are responsible remain to be
elucidated.
The steady state level of mitochondrial messenger RNAs
(mt-mRNAs) is known to be substantially increased when
mitochondrial translation is terminated by protein synthesis
inhibitors such as thiamphenicol (TAP) [12,13]. In our current
study, we have addressed the question of whether this increase
is orchestrated at least in part by the proliferation mechanism
or whether the process is autonomous to the mitochondrion.
We were unable to detect any change in the levels of candidate
nuclear-encoded transcripts or proteins. However, a new spe-
cies of polyadenylated transcript was shown to accumulate in
mitochondria of liver cell lines after treatment with TAP. This
accumulation was temporally distinct from the global increase
in mtDNA transcription and may indicate a novel mechanism
for regulating mtDNA copy number.
2. Materials and methods
2.1. Materials and cell lines
All radiochemicals were from Amersham UK. Chemicals including
TAP, tissue culture medium, foetal calf serum (FCS) and supplements
were from Sigma-Aldrich, UK, whilst chick embryo extract was from
ICN-Flow. Tissue culture plastic was from Corning-Costar UK Ltd.
Cells were cultured in Eagle’s minimal essential medium, 10% FCS, 2
mM L-glutamine and non-essential amino acids, and where required,
supplemented with 1 mM pyruvate and 50 Wg ml31 uridine. TAP was
dissolved in ethanol, the concentration calculated spectrophotometri-
cally (OmM = 0.64 at 273 nm) and administered at 50 Wg ml31 ¢nal
concentration; control cells were supplemented with an equal volume
of ethanol. Oligonucleotides (30 nmol) were synthesised in the molec-
ular biology facility (University of Newcastle upon Tyne, UK).
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2.2. RNA and DNA
2.2.1. RNA extraction and Northern analysis. Total cytosolic
RNA was isolated using Ultraspec II RNA (Biotex lab Inc., USA)
following manufacturer’s instructions. DNase treatment of RNA was
performed with RNase-free DNase I (22 U, Boehringer Mannheim),
followed by phenol extraction and precipitation. mRNA was ex-
tracted from total cytosolic RNA preparations following manufactur-
er’s instructions (Qiagen Oligotex mRNA mini kit). RNA samples (10
Wg) were subjected to Northern analysis as detailed in [13], blots were
hybridised with DNA probes at 42‡C or RNA probes at 55‡C fol-
lowed by stringent washes and PhosphorImage analysis (Molecular
Dynamics). Blots were stripped as detailed in [13].
2.2.2. Fine mapping of RNA DL-L (RNA D-loop L-strand). To
determine the 3P-terminus of this polyadenylated species, reverse tran-
scription (RT) was performed on 5 Wg of DNase-treated RNA from
TAP-treated cells as recommended using Superscript II pre-ampli¢ca-
tion kit (Gibco BRL), with a T30A/C/G-tagged (5P-CTACCAACTC-
GAGAGGATCT30A/C/G-3P) oligodeoxynucleotide primer mix. Sub-
sequent polymerase chain reaction (PCR) was performed with a
primer identical to residues 467^486 of the light (L)-strand (5P-CCCA-
TACTACTAATCTCATC-3P) in tandem with a primer speci¢c to the
T30A/C/G tag (5P-CTACCAACTCGAGAG-3P). The resultant ap-
proximately 170 bp product was cloned into pCR-Script (Stratagene)
and a number of clones subjected to automated DNA sequence anal-
ysis. To map the 5P-terminus, a primer extension method was em-
ployed, described in [14]. A primer mapping to heavy (H)-strand
residues 16 215^16 196 (5P-TGCTGTACTTGCTTGTAAGC-3P) was
end-labelled with [Q-32P]ATP (3000 Ci mmol31) using T4 polynucleo-
tide kinase and 100 ng was hybridised with 10 Wg RNA overnight at
37‡C in 80% (v:v) formamide, 40 mM PIPES pH 6.4, 1 mM EDTA
and 0.4 M NaCl. This was precipitated twice and resuspended accord-
ing to Superscript II pre-ampli¢cation kit instructions for RT. Super-
script II RT enzyme (50 U) was added and RT allowed to proceed for
1 h at 42‡C. The reaction was ethanol-precipitated and electrophoresed
through a 6% polyacrylamide 7 M urea gel, together with a sequencing
ladder derived from M13^40 oligomer-primed M13 ssDNA (Seque-
nase version 2.0). The gel was dried and analysed by phosphorImage.
2.2.3. Southern analysis. DNA was isolated from control and
TAP-treated cells by overnight incubation with proteinase K (2 mg
ml31) and sodium dodecyl sulphate (SDS; 1% (w:v)) at 37‡C, fol-
lowed by phenol extraction and precipitation. Aliquots were digested
with PvuII and electrophoresed through a 0.7% agarose gel in
1UTAE bu¡er (40 mM Tris^acetate, 1 mM Na2EDTA, pH 8.0).
Transfer to Genescreen Plus membrane (NEN DuPont) and probing
were performed following manufacturer’s instructions.
2.2.4. DNA and RNA probe production. DNA probes for North-
ern and Southern analyses were prepared by random primer extension
(20^30 ng of template DNA) in the presence of [K-32P]dCTP (3000 Ci
mmol31) and unincorporated nucleotides removed (Pharmacia nick
columns). Template DNA was generated by PCR for mitochondrial
sequences or RT-PCR for the remainder. Primers used to generate
mtDNA probes corresponded to: probe 2d, L-strand residues 467^486
in tandem with H-strand residues 680^665; probe 3d, L-15 950^15 964
with H-16 060^16 033; probe 4d, L-371^389 with H-530^548; ND1
probe, L-3384^3403 with H-4233^4250; ND-6 probe, L-14 201^14 217
with H-14 650^14 631; 12S mtDNA, L-915^933 with H-1289^1272.
Primers were designed for RT-PCR of transcripts encoding mtTFA,
NRF-1 and mt-SSB from sequences in the GenBank database. PCR-
generated fragments were cloned into pCR-Script and con¢rmed by
DNA sequence analysis. The remaining probes were gifts.
Riboprobes were generated by in vitro transcription using an SP6/
T7 Stratagene kit supplemented with 50 WCi [K-32P]UTP (800 Ci
mmol31) and template (1 Wg linearised plasmid or 300 ng PCR prod-
uct). Probes were puri¢ed following separation on 5% denaturing
polyacrylamide gel, the radiolabelled RNA excised, eluted (0.5 M
ammonium acetate, 1 mM EDTA, 0.2% SDS (w:v)) and then precipi-
tated. To determine the strand speci¢city of RNA DL-L, two probes
were in vitro transcribed from a PCR-derived template (PCR primers:
5P-CCCTATAGTGAGTCGTATTACTCCACCATTAGCACCCAA-
AG-3P with 5P-GATTTAGGTGACACTATAGATTTCACGGAGG-
ATGGTG-3P). This 482 bp PCR fragment spans the mtDNA dis-
placement (D)-loop from residues 15 974^16 419 and incorporates
phage T7 and SP6 recognition sites at opposite termini, allowing
the synthesis of riboprobes that bind transcripts with H-strand or
L-strand sequences, respectively.
2.3. Mobility shift assays
NRF-1 and AP-1 mobility shift assays were performed by the meth-
od of [5] on nuclear protein extracts prepared at 4‡C as described in
[15]. Reactions were separated on 5% non-denaturing polyacrylamide
gel and PhosphorImage analysed.
2.4. Western analysis
Cell lysates were prepared by shearing cells at 4‡C in 2% (v:v)
Nonidet P-40, 50 mM Tris pH 7.5, 130 mM NaCl before adding an
equal volume of 50 mM Tris^HCl pH 7.5. Both bu¡ers contained the
following protease inhibitors at ¢nal concentrations of 1 mM phenyl-
methylsulfonyl £uoride, 5 Wg/ml leupeptin, 1 Wg/ml antipain, 1 mM p-
aminobenzamidine. Aliquots of cell lysate from control and TAP-
treated cells were electrophoresed for 1200 V h through 15% (w:v)
SDS^polyacrylamide gel and proteins transferred to Immobilon
PVDF membrane (Millipore) in CAPS bu¡er (10 mM CAPS, 10%
methanol, pH 11) for 3 h at 295 mA. Membranes were probed with
antisera (mtTFA, p43, crotonase, COX lV, cpn10, cpn60, mTERF)
and secondary antibodies conjugated to horseradish peroxidase. Sig-
nals were detected by enhanced chemiluminescence (Amersham, UK).
2.5. Estimation of cell doubling times
Hep G2 cells were seeded at 10% con£uency in 16 mm wells. Cul-
tures were fed every alternate day and split at 80% con£uency. Each
time point was duplicated and the experiment repeated such that each
point was assayed in quadruplicate. Cell number measurements were
made on a Z1 Coulter counter (100 Wm aperture size, 1 ml metered
volume).
3. Results
3.1. TAP treatment does not a¡ect the cellular level of mtDNA
In Hep G2 cells treated with TAP for 11 days, the steady
state levels of mt-mRNA transcripts increase without a con-
comitant increase in mitochondrial ribosomal RNAs (mt-
rRNAs) [13]. There was no measurable e¡ect on mt-mRNA
stability, but without determining the cellular content of
mtDNA, it could not be concluded unequivocally that TAP
treatment resulted in an upregulation of transcription. South-
ern analysis (Fig. 1) shows that the relative levels of nuclear
and mtDNA are similar in control and TAP-treated cells,
demonstrating that the previously reported increase in steady
state mt-mRNA levels was due to a selective increase in the
rate of production of the two H-strand polycistronic RNA
units.
Fig. 1. Treatment with TAP does not a¡ect total cellular mtDNA
content. DNA was isolated from both untreated (Cont) and 11 day
TAP-treated cells and the indicated amount was subjected to South-
ern analysis as described in Section 2. A representative result is
shown. Relative levels of nuclear and mtDNA were determined fol-
lowing hybridisation with probes to the 18S rDNA and 12S rDNA,
respectively. Signal intensities were calculated for both probes in the
control (0.5 Wg) sample and the ratio normalised to 100%. Relative
intensities were calculated for each sample and compared to the
control (shown under each lane).
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3.2. Levels of NRF-1 and mtTFA are una¡ected in cells treated
with TAP
The relative levels of NRF-1 DNA-binding activity were
assessed by gel-mobility shift analysis using nuclear extracts
isolated from TAP-treated and control Hep G2 cells. No ap-
preciable di¡erence in the amounts of binding active-NRF-1
protein (Fig. 2A) or transcript (RPA assay, data not shown)
was detected between control and TAP-treated cells. In agree-
ment both with this and with the absence of any TAP-induced
increase in the steady state levels of mtDNA shown in Fig. 1,
Western analysis of whole cell lysates revealed that TAP treat-
ment did not alter the levels of mtTFA protein (Fig. 2B).
Further, there was no appreciable di¡erence in transcript lev-
els or the encoded polypeptides of other mitochondrial pro-
teins that have been postulated to play a role in modulating
mitochondrial gene expression (Fig. 2C).
3.3. TAP treatment results in the production of a novel
mitochondrial RNA species
In light of previous suggestions that antisense molecules
encoded within the D-loop region may regulate mammalian
mtDNA replication and transcription [16,17], a D-loop-spe-
ci¢c probe was made and used to assess transcription through
this region of the genome. As illustrated in Fig. 3, no D-loop
transcript was detectable in the untreated Hep G2 RNA. 11
day treatment with TAP, however, resulted in marked expres-
sion of an approximately 1200 nucleotide (nt) species and, to
a lesser degree, an approximately 900 nt species. Further, both
species were detectable in mt-mRNA fractions puri¢ed
through oligo dT a⁄nity columns, con¢rming that they
were polyadenylated (data not shown). Strand-speci¢c RNA
probes showed that both species were transcribed from the H-
strand (Fig. 3A). Whilst an approximately 800 nt D-loop spe-
cies has been reported in human HeLa cells [16], to our
knowledge the larger D-loop species reported here has never
been documented. Crude mapping experiments were at-
Fig. 2. TAP treatment does not a¡ect the levels of products from
various candidate nuclear genes. In all cases, examples shown are
representative of at least three repeat time courses. A: NRF-1
DNA-binding activity is not a¡ected by TAP. Nuclear lysate (40
Wg) from control and 11 day TAP-treated Hep G2 cells was incu-
bated with radiolabelled probes as detailed in Section 2. No appreci-
able di¡erence in NRF-1-binding activity could be shown (cf. lanes
3 and 4). Probe speci¢c for AP-1 binding was used as an internal
control. A small amount of non-speci¢c protein binding to the
NRF-1 probe was found, with the resultant complex having a simi-
lar mobility to the AP-1 complex (lanes 5 and 6). B: TAP does not
induce a modulation in the levels of mtTFA. Cytoplasmic lysate
was prepared from both control and TAP-treated Hep G2 cells after
the indicated number of days in TAP. Samples (75 Wg) were sub-
jected to Western analysis as detailed in Section 2. Comparison of
the protein levels revealed by antibodies speci¢c to mtTFA and to
the internal control (the mitochondrial L-oxidation enzyme croto-
nase) showed no e¡ect upon TAP treatment. C: Steady state levels
of candidate nuclear gene products were unaltered by growth of
cells in TAP. Panel 1: As with (B), cytoplasmic lysates were sub-
jected to Western analysis with antibodies to chaperonin 60, chaper-
onin 10, mitochondrial efTu and glutamate dehydrogenase (as a
control) with no evident e¡ect with TAP treatment. Panel 2: RNA
(10 Wg) from both 11 day TAP-treated and control Hep G2 cells
were subjected to Northern analysis. Neither TAP treatment (lanes
1 and 3) nor pyruvate and uridine addition (lanes 3 and 4) appeared
to a¡ect the steady state level of the transcripts studied.
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tempted with three other D-loop probes as shown in Fig. 3B,
showing the 1200 nt species to span approximately the entire
D-loop. Probes 2 and 4 did not detect the 900 nt species,
consistent with it terminating within the conserved sequence
box CSB1, reported to be the natural termination site for the
large H-strand polycistronic transcript [16]. To accurately
map the 5P- and 3P-termini of the major 1200 nt transcript,
primer extension and RT-PCR were used. The 5P-proximal
Fig. 3. A novel D-loop-encoded RNA species is induced by TAP treatment. Total cytoplasmic RNA (10 Wg) isolated from TAP-treated and
control cells was subjected to Northern analysis with various probes. A: Determination of strand speci¢city of D-loop transcripts. Riboprobes
speci¢c to region 1 of either D-loop strand were prepared and hybridised to the membrane as detailed in Section 2. Results show that two D-
loop transcripts were present and both were H-strand in origin. A 12S rRNA probe and L-actin (not shown) were used as controls. B: Crude
mapping of the D-loop transcripts. Crude mapping of transcript positioning was performed by using probes designed to speci¢c regions of the
D-loop (as indicated in C(iii)) and speci¢ed in Section 2. C: Fine mapping of the 1200 nt D-loop transcript. The 5P-terminus was determined
by primer extension by standard methods. To determine the 3P-terminus of the polyadenylated D-loop species, RT-PCR was performed as de-
tailed in Section 2 and the subsequent products were subjected to DNA sequence analysis. A schematic of the relative position of this 1192 nt
RNA is shown. The initiating 5P-residue corresponds to the nucleotide between mt-tRNAs Pro and Thr and terminates beyond the HSP initiation
site (the precise initiating base is underlined) at the ¢nal residue preceding mt-tRNAPhe.
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residue was determined to be nt 15 954, the single residue
between the genes encoding mt-tRNAPro and mt-tRNAThr.
The 3P-terminal residue, nt 576, was the ¢rst base 5P-proximal
to mt-tRNAPhe (Fig. 3C). Thus, the complete 1192 nt H-
strand transcript runs through the entire D-loop and past
the major H-strand promoter IH1, consistent with this tran-
script being processed from a larger polycistronic unit that
may have been generated by run on transcription through
the D-loop. We have termed this unique species RNA DL-L.
3.4. Temporal production of RNA DL-L is distinct from the
increased production of mt-mRNAs
The identi¢cation of this novel RNA species in TAP-treated
Hep G2 and other liver cell lines (data not shown) raises the
possibility that RNA DL-L could remain bound to the H-
strand, occluding IH1, thus promoting initiation from a second
H-strand promoter IH2. Transcriptional initiation from this
second promoter has been implicated in the di¡erential H-
strand transcription that occurs in response to thyroid hor-
mone treatment [18]. To address this possibility, total cyto-
plasmic RNA was isolated from untreated Hep G2 cells and
after various incubation times in TAP (Fig. 4). Although
RNA DL-L becomes detectable at day 3, the major induction
of this species did not occur until 7 day treatment, well after
the increased transcription of the mt-mRNAs which reaches a
maximum after 3 days. The induction of RNA DL-L is, there-
fore, likely to involve a mechanism distinct from that respon-
sible for the increase in mt-mRNAs.
No substantial reading frame is present in the D-loop re-
gion of the corrected Cambridge Reference mtDNA sequence
[19]. As the function of RNA DL-L is unknown, one potential
explanation is that RNA DL-L is edited to produce a mt-
mRNA that could encode a protein induced under conditions
of mitochondrial stress. RNA editing is a common mechanism
in the mitochondria of numerous species [20], although there
has never been a report of such a process in human mitochon-
dria. DNA sequence analysis was performed for the D-loop
region of Hep G2 mtDNA and was compared to the sequence
of RNA DL-L after RT-PCR. As shown in Table 1, although
there were several changes from the reference sequence, all the
alterations found in RNA DL-L were also found in the cor-
responding mtDNA. An alternative role for this molecule is in
the regulation of mtDNA replication. Fig. 4 shows the stan-
dard growth curve of Hep G2 cells in TAP-treated and con-
trol cells. Cell division time in untreated cells is 30 h, a rate
that is similar to cells grown in TAP for up to 4 days. How-
ever, the major e¡ect on cell turnover occurs around the 4^5
day mark, just as the expression of RNA DL-L becomes ap-
parent.
4. Discussion
TAP treatment causes an increase in mtDNA transcription
without the modulation of nuclear gene expression that can
a¡ect mtDNA expression. What, therefore, is the mechanism
that underlies this autonomous regulation? It has been specu-
lated that autonomous regulation could be controlled by the
transcriptional termination activity of the termination com-
plex, mTERF [21]. A decrease in binding a⁄nity for this
site might be predicted to attenuate transcription termination,
leading to increased synthesis of the mt-mRNA species down-
stream. The components of this complex and indeed the mo-
lecular mechanisms underlying truncation of H-strand tran-
scription have not been fully described. Originally, a partially
puri¢ed mtDNA DNA-binding and transcription termination
activity termed mTERF [22] (or mtTERM [23]) was identi¢ed
in a group of proteins ranging from 31 to 36 kDa [24]. The
Fig. 4. The increase in steady state levels of RNA DL-L is tempo-
rally distinct from the TAP-induced global increase in mt-mRNA.
A: E¡ect of TAP treatment on growth of Hep G2 cells. Identical
numbers of cells were seeded into culture wells and incubated with
control or TAP medium. Wells were seeded in duplicate and har-
vested at daily intervals, the contents were counted using a Coulter
counter. Each point on the semi-log plot represents the mean of
four measurements. Control and TAP-treated cells behave in an
identical fashion for the ¢rst 4 days after which TAP-treated cells
dramatically decrease the growth rate. B: Temporal analysis of
RNA DL-L following TAP treatment. A Northern blot was pre-
pared with 10 Wg samples from control and TAP-treated (1^11
days) Hep G2 cells. The 18S rRNA was used as a loading control.
Probes to RNA DL-L reveal an induction of expression after
3 days in TAP, reaching maximal expression after 7 days. Probes to
mt-mRNA species (ND1 is shown) show the expected increase in
steady state levels even after a single day, but maximum expression
in each case occurs after 3 day TAP exposure.
Table 1
Changes from the mtDNA reference sequence found in both RNA
DL-L and D-loop
Nucleotide
position
Base change Nucleotide
position
Base change
16 182 ACC 16 519 TCC
16 183 ACC 73 GCA
16 189 TCC 263 ACG
16 217 TCC 317 CCG
16 223 CCT 332 CCG
16 295 CCT
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most abundant of these species, a 34 kDa polypeptide, is also
known as mTERF. This 34 kDa component alone is capable
of DNA-binding activity but is not su⁄cient to terminate
transcription in vitro [25]. It was also speculated that modu-
lating intramolecular interactions could alter DNA-binding
a⁄nity of this component. In cytoplasmic lysates, we were
able to detect a protein complex that bound speci¢cally to a
probe carrying the tridecamer mTERF DNA-binding se-
quence [26]. The control probe carrying a short deletion was
not bound, as predicted. A decrease in binding complex was
consistently noted in cell lysates following TAP treatment
(data available on request). However, following exhaustive
immunological experimentation we were unable to con¢rm
the presence of the 34 kDa subunit in this complex. As we
had attempted to protect the intact binding complex, it is
possible that polyclonal antibodies raised against puri¢ed
mTERF could not access the component. An alternative ex-
planation is that the binding complex we see either does not
contain mTERF or is an artifact.
A second possibility to explain the TAP-induced di¡erential
in H-strand transcription is that TAP promotes initiation
from the second H-strand promoter IH2, in a comparable
manner to that proposed for thyroid hormone treatment, re-
sulting in a similar di¡erential increase in mt-mRNA over mt-
rRNA gene transcription. This selective increase is believed to
be mediated by a truncated form of c-erbA-K1 acting as a
mitochondrial T3 receptor [27]. Binding to the receptor may
promote transcription from IH2, resulting in a product, which
is not terminated by mTERF. Further experimentation will be
necessary to elucidate the exact mechanisms responsible for
this di¡erential transcription.
In response to TAP treatment, a novel mtRNA species
RNA DL-L is generated. In contradistinction to the increase
in the levels of mt-mRNAs, which reached a maximum after
3 day treatment, maximal levels of RNA DL-L are present at
between 5 and 7 days, just after the TAP-induced decrease in
cell turnover. As the cell turnover rate is diminished, the rate
of mtDNA replication or turnover must compensate to main-
tain the cell copy number of mtDNA. One potential role for
this novel species is, therefore, to inhibit the rate of mtDNA
replication. It is well documented that the L-strand promoter
(LSP)-initiated RNA transcribed through the CSBs within the
D-loop has an unusually high a⁄nity for template DNA and
remains bound, forming an R-loop hybrid [28]. The bound
RNA acts to prime DNA synthesis from the LSP [29].
RNA DL-L may invade the RNA/DNA hybrid to form a
very stable RNA duplex. Blocking the formation of the
RNA/DNA hybrid around the CSB regions would prevent
maturation of the LSP-initiated RNA primer by MRP RNase,
consequently preventing mtDNA replication. Although we
have limited data to support this speculation, such an anti-
sense mechanism is known to regulate the copy number of the
ColE1 replicon in bacteria [30]. How is RNA DL-L formed?
Thirty years ago, Attardi et al. reported that, at least in HeLa
cells, the entire mtDNA molecule was transcribed [31]. It is
therefore possible that this species is normally generated but
has a very short half-life. Stabilisation of RNA DL-L by a
currently unknown mechanism may therefore be all that is
necessary for it to function as an antisense regulator.
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